Effects of intravenous streptokinase and CLS 2210 (calcium dobesilate) on the biochemical markers of early acute myocardial infarction: a historic comparison with both studies.
In a previous double-blind, randomized study, CLS 2210 (a new formulation of calcium dobesilate) or placebo was administered by intravenous infusion to 41 patients having their first acute myocardial infarction. In the present study 19 comparable patients were treated intravenously with streptokinase under identical conditions and the results compared with those from the previous study. In all patients administration was begun within three hours of onset of symptoms and continued over seventy-two hours. Blood samples were taken for the measurement of serum activity of creatine kinase and its isoenzyme MB, and the serum and urinary concentrations of myoglobin and glycosaminoglycans were also measured. The purpose of this study was to determine the effects of CLS 2210, placebo, and streptokinase on these biochemical markers of acute myocardial infarction, thereby assessing their actions in limiting myocardial necrosis. In the CLS 2210-treated patients, the levels of serum creatine kinase and serum and urinary myoglobin were significantly lower than in the placebo patients throughout the seventy-two hours (p = 0.01, 0.005, 0.004 respectively). The levels of creatine kinase MB and serum glycosaminoglycan in the CLS 2210 patients were initially higher than in the placebo patients but fell below placebo levels between the fortieth and fifty-fifth hours, respectively (p = 0.89, 0.02). Only the glycosaminoglycan urinary concentrations were higher in the CLS 2210 group than in the placebo group throughout (p = 0.0005). The values for the six variables investigated showed no statistically significant difference between placebo and streptokinase.(ABSTRACT TRUNCATED AT 250 WORDS)
Szlavy
L
L
Department of Diagnostic Radiology, National Institute of Cardiovascular Surgery, Budapest, Hungary.
Repa
I
I
Lengye
I
I
Lamboy
L
L
D001557:Benzenesulfonates / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D006025:Glycosaminoglycans / Q000378:metabolism; D006801:Humans; D007262:Infusions, Intravenous; D007527:Isoenzymes; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy*; D009211:Myoglobin / Q000378:metabolism; D013300:Streptokinase / Q000008:administration & dosage / Q000627:therapeutic use*
D001557:Benzenesulfonates; D015415:Biomarkers; D006025:Glycosaminoglycans; D007527:Isoenzymes; D009211:Myoglobin; C046114:CLS 2210; D003402:Creatine Kinase; D013300:Streptokinase